About This Calculator

The Nivolumab (Opdivo) Dosing Schedule Calculator is designed to assist healthcare professionals in mapping out potential treatment timelines for patients. By selecting an approved indication and specific regimen, the tool generates a detailed schedule of administration dates based on the chosen start date and number of cycles. This facilitates planning for both monotherapy and combination therapy with ipilimumab, accommodating flat-dosing and weight-based protocols.

Understanding the Outputs

Upon successful calculation, the tool generates a comprehensive table detailing the administration schedule. Each row in the table represents a single treatment cycle and includes the following information:

• Cycle: The sequential number of the treatment cycle (e.g., 1, 2, 3).
• Date: The projected date for drug administration for that cycle.
• Nivolumab (Opdivo) Dose (mg): The calculated dose of nivolumab for the cycle. This will be a fixed value for flat-dose regimens or a calculated value for weight-based regimens.
• Ipilimumab (Yervoy) Dose (mg): Displayed for combination regimens, this shows the calculated dose of ipilimumab. For nivolumab monotherapy cycles, this will indicate '—'.
• Notes: Provides context for the cycle, such as "Nivo only" or "Nivo + Ipi," helping to distinguish between induction and maintenance phases.

How to Use the Calculator

To generate a dosing schedule, follow these steps:

1. Select Indication: Choose the appropriate clinical indication from the first dropdown menu (e.g., Metastatic Melanoma, NSCLC).
2. Select Regimen: Based on the indication, select the specific treatment regimen (e.g., Nivolumab Monotherapy, Nivolumab + Ipilimumab).
3. Select Dosing Interval / Detail: Choose the specific dosing frequency and strength (e.g., 240 mg every 2 weeks).
4. Enter Patient Weight (if required): For weight-based regimens, the patient weight field will appear. Enter the weight in kilograms (kg).
5. Set Treatment Start Date: Use the date picker to select the first day of treatment.
6. Set Number of Cycles: Enter the total number of cycles you wish to map out in the schedule.
7. Calculate: Click the "Calculate Schedule" button to generate the results.

Nivolumab Dosing Overview

Nivolumab dosing varies significantly based on the indication and whether it is used as a monotherapy or in combination. The calculator reflects approved dosing strategies, which generally fall into these categories:

• Flat-Dose Monotherapy: A fixed dose is administered regardless of patient weight, typically 240 mg every 2 weeks or 480 mg every 4 weeks. This is common in adjuvant melanoma and previously treated NSCLC.
• Weight-Based Combination Therapy (Induction/Maintenance): In some regimens for melanoma or renal cell carcinoma, treatment begins with an induction phase of weight-based nivolumab plus ipilimumab for a set number of cycles (e.g., 4 cycles). This is followed by a maintenance phase of flat-dose nivolumab monotherapy.
• Weight-Based Dual Frequency Therapy: For certain first-line NSCLC patients, nivolumab is given at one frequency (e.g., every 2 weeks) while ipilimumab is given at a different, less frequent interval (e.g., every 6 weeks).

Switching Between Dosing Schedules

The prescribing information for nivolumab allows for flexibility in some indications, such as switching between 240 mg every 2 weeks and 480 mg every 4 weeks. This decision should be based on clinical judgment, patient convenience, and institutional protocols. This calculator requires users to select one consistent schedule for the duration of the calculation. To model a switch, you would need to run a new calculation starting from the date of the switch.

Managing a Missed Dose

This calculator does not provide guidance on managing missed or delayed doses. Clinical judgment is required to determine the best course of action. Factors to consider include the length of the delay and the patient's clinical status. Always refer to the full prescribing information and consult with the oncology pharmacy for institutional guidelines on treatment delays.

Important Safety Alerts

Frequently Asked Questions (FAQ)

Why is the patient weight field sometimes required and sometimes hidden?

The patient weight field only appears when a weight-based dosing regimen is selected. For flat-dose regimens (e.g., 480 mg Q4W), weight is not needed for the calculation, so the field remains hidden to simplify the interface.

How does the calculator handle the induction and maintenance phases for melanoma/RCC?

For regimens like "Nivo 3 mg/kg + Ipi 1 mg/kg Q3W x 4 doses, then Nivo 480 mg Q4W," the tool first calculates the 4 combination induction cycles based on the 21-day frequency. It then calculates the subsequent maintenance cycles of nivolumab monotherapy using the 28-day frequency, starting after the last induction cycle.

Does this schedule adjust for dose reductions due to toxicity?

No. The calculator generates an ideal schedule based on standard dosing. It does not account for any dose modifications, delays, or discontinuations that may be necessary due to adverse events. All such adjustments must be managed by the treating clinician.

Can I use this tool for indications not listed in the dropdown menu?

No. The tool is programmed only with the specific FDA-approved indications and regimens listed. It should not be used to extrapolate schedules for other cancer types or off-label uses.

What happens if a calculated administration date falls on a weekend or public holiday?

The calculator performs a pure date calculation and is not aware of weekends or holidays. The generated schedule is a projection, and clinical staff must adjust the actual appointment dates to fit the operational hours of the infusion center.

How is the dual-frequency schedule for NSCLC calculated?

For the "Nivo 3 mg/kg Q2W + Ipi 1 mg/kg Q6W" regimen, the tool calculates a nivolumab date every 14 days. It then adds an ipilimumab dose to every third nivolumab administration, starting with the very first cycle (Cycle 1, 4, 7, etc.), reflecting the 6-week (42-day) interval for ipilimumab.

Is this calculator a substitute for the official Prescribing Information?

Absolutely not. It is a supplementary planning tool. The full, most current Prescribing Information is the only official source for dosing, administration, and safety information and must always be consulted.

What if my patient's weight changes during treatment?

For weight-based regimens, doses should be recalculated if the patient's weight changes significantly, per institutional policy. This tool calculates all doses based on the single weight entered at the start and does not account for changes over time.

References

1. OPDIVO® (nivolumab) injection, for intravenous use. U.S. Prescribing Information. Bristol-Myers Squibb Company.
2. Opdivo (nivolumab) European public assessment report (EPAR). European Medicines Agency.
3. Opdivo® (nivolumab) Official Site for Healthcare Professionals. Bristol-Myers Squibb.
4. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med. 2019;381(16):1535-1546. doi:10.1056/NEJMoa1910836